United States President Donald Trump has launched TrumpRx, a new website that he says will lower the cost of prescription medicines, which have long stood out for their sky-high prices in the US compared with similar products around the world.
The new website allows consumers to buy discounted drugs directly from pharma companies.
Trump said at the site’s unveiling that some of the world’s largest drug producers have agreed to bring down prices under “Most Favoured Nation” agreements in exchange for avoiding US tariffs.
According to the White House, the website is launching with savings on more than 40 popular drugs.
“You’re going to save a fortune and this is also so good for overall health care.”
Donald Trump
The government-hosted website is not a platform for buying medications. Instead, it’s set up as a facilitator, pointing Americans to drugmakers’ direct-to-consumer websites, where they can make purchases. It also provides coupons to use at pharmacies
Users can search the site for the medication they want, then print out a coupon and present it at a pharmacy to buy at the discounted price.
The Trump administration has pitched the initiative as a populist attack on powerful pharmaceutical companies amid growing discontent over the state of the economy.
A group of 16 drug companies have agreed to discount deals, under which they will offer lower prices for certain drugs to government programmes such as Medicaid and, via TrumpRx, to US consumers.
The TrumpRx site, which promises “the world’s lowest prices on prescription drugs,” showcases more than 40 medications, including weight-loss drugs such as Ozempic and Wegovy, and calls the effort “the most impactful prescription price reset in the history of our country.” “Thanks to President Trump, the days of Big Pharma price-gouging are over,” the website states.
The site is part of a larger effort by the Trump administration to show it’s tackling the challenges of high costs. Affordability has emerged as a political vulnerability for Trump and his Republican allies going into November’s midterm elections, as Americans remain worried about the cost of housing, groceries, utilities and other staples of middle-class identity.
Trump stressed that the lower prices were made possible by his pressuring of pharmaceutical companies on prices, saying he demanded that they charge the same costs in the US as in other nations. He said prescription drug costs will increase in foreign countries as a result.
Questions Over Effort Addressing Drug Prices
However, analysts have questioned whether the effort will substantively address US drug prices or shake up the pharmaceutical industry.
The administration is touting substantial discounts, though it’s unclear just how much impact the changes will have for family budgets. The site includes the disclaimer that prices “may be even lower” for people with insurance, as it lists the “out-of-pocket price.” Also, some consumers might be able to use available generics that cost less than brand-name medications.
Juliette Cubanski, Deputy Director for Medicare policy at health policy organisation KFF, told a news agency that there is a real question about the value of this for people with insurance. “In some cases, we could be looking at out-of-pocket costs that are still relatively unaffordable for a lot of people,” Cubanski said.
A previous analysis by KFF stated that the details of the Most Favoured Nation agreements with the firms “remain confidential, which means that very little is known publicly about what exactly has been agreed to.”
Pharmaceutical companies remain a powerful force in US politics, with the watchdog group Open Secrets reporting that pharmaceutical manufacturers spent a record-high $187m on lobbying activities in 2025.
Many of the details of Trump’s deals with manufacturers remain unclear, and drug prices for patients in the US can depend on many factors, including the competition a treatment faces and insurance coverage.
Most people have coverage through work, the individual insurance market or government programs like Medicaid and Medicare, which shield them from much of the cost.
READ ALSO: Big Push Funds Prioritize Road Infrastructure to Spur Transformation – Mahama
